[An effect of 3-oxypyridine and succinic acid derivatives on the time of reduction of anxiety and depression symptoms in alcohol withdrawal treatment]. / Vliyanie proizvodnykh 3-oksipiridina i yantarnoi kisloty na temp kupirovaniya simptomov trevogi i depressii v protsesse lecheniya sindroma otmeny alkogolya.

OBJECTIVE: To compare the effect of 3-oxypyridine and succinic acid derivatives (emoxypine, reamberin, mexidol) on the time of reduction of anxiety and depression symptoms in the standard treatment of alcohol withdrawal syndrome (AWS). MATERIAL AND METHODS: A short-term prospective placebo-controlled double blind randomized study of the effect of emoxypine, reamberin, mexidol on the dynamics of reduction of anxiety and depression clinical symptoms in the course of a 14-day day hospital treatment of AWS was conducted. The severity of anxiety symptoms was assessed on a daily basis by using the Hamilton Anxiety Rating Scale (HARS). Symptoms of depression were assessed with the Montgomery-Asberg Depression Rating Scale (MADRS). Reduction of certain objective anxiety and depression symptoms was noticed at 0 point of the corresponding HARS and MADRS items. On the 1st and 14th day of treatment, the Zung Self-Rating Anxiety Scale (ZSRAS) and the Beck Depression Inventory (BDI) were additionally used. RESULTS AND CONCLUSION: All the studied drugs reduced the duration of certain anxiety and depression symptoms during AWS treatment. The degree of this effect depended on the features of the chemical structure of a drug. Mexidol accelerated the reduction of «dread¼, «respiratory¼ and «cardiovascular¼ anxiety symptoms (HARS) by 25-50%. «Reduced appetite¼ and «concentration difficulty¼ (MADRS) improved by 28.5%. Reamberin reduced the duration of «gastrointestinal¼ and «respiratory¼ anxiety symptoms (HARS) by 17-50% and «inner tension¼ (MADRS) by 7%. Emoxypine accelerated the reduction of «insomnia¼ and «respiratory¼ symptoms (HARS) but did not affect the duration of objective depression symptoms (MADRS). Emoxypine and reamberin reduced the severity of affective and cognitive symptoms (BDI) by 32-37%. None of the drugs affected self-reported anxiety (ZSRAS). The most balanced treatment of depressive symptoms was provided by reamberin, which was the only of the studied drugs that simultaneously reduced both the duration of objective symptoms and the severity of subjective disorders of affective status in alcohol withdrawal.

[Atherosclerosis of peripheral arteries in patients with coronary artery disease and type 2 diabetes mellitus].

AIM: To study the features of atherosclerosis of peripheral arteries in patients with coronary artery disease (CAD) depending on the presence of type 2 diabetes mellitus (T2DM) and to identify factors associated with multifocal atherosclerosis. MATERIALS AND METHODS: The study included 140 patients (77 men and 63 women) with CAD (mean age 62.0 (56.0-66.0) years). The first group included 70 people with CAD and T2DM, and the second group included 70 patients with CAD without T2DM. All patients underwent duplex scanning of the carotid and lower limb arteries (LLA). Local vascular stiffness of the common carotid artery (CCA) was assessed by ultrasound scanning. The Peterson elasticity modulus, distensibility and strain of the CCA were determined. The ankle - brachial index (ABI) was measured by the Doppler method. RESULTS AND DISCUSSION: In the group of patients with T2D, there were statistically more patients with atherosclerotic plaques in both carotid arteries and LLA. Also among patients with T2DM the severity of stenosis of carotid arteries and LLA at all levels was significantly greater. Local carotid stiffness was higher in the first group of patients. The proportion of individuals with reduced ABI.